News

The first oncology therapeutic biosimilars are now available in the United States.
In addition to a natural variation in genetic makeup, approximately 1 in 1000 people inherit a damaged or mutated copy of the BRCA1 gene from a parent.
Top news of the week from Specialty Pharmacy Times.
Top news of the day from across the health care landscape.
Individuals with HIV maintained similar rates of viral suppression after switching from a 3-drug regimen to the 2-drug regimen of dolutegravir plus lamivudine.
Photobiomodulation therapy found effective for the prevention of oral mucositis caused by radiation therapy.
Top news of the day from across the health care landscape.

Product News

Granix is a human granulocyte factor produced in a bioreactor using recombinant DNA technology.
Complera treats HIV infection in previously untreated adults with a viral load of 100,000 copies/mL or less.
Repatha (evolocumab) treats primary hyperlipidemia in combination with dietary measures and maximally tolerated doses of statins.
Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate) is approved for treatment of HIV-1 infection.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2019
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$